Bicycle Therapeutics (BCYC) Interest Coverage Ratio (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Interest Coverage Ratio came in at 15.16 in Q2 2026, up 53.51% YoY from 9.88 in Q2 2025, and up 16.82% on a QoQ basis from 18.22 in Q1 2026.
Bicycle Therapeutics (BCYC) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Interest Coverage Ratio data on file, last reported at 15.16 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 53.51% year-over-year to 15.16 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 58.43 (up 46.17% YoY) and the FY2025 annual result came in at 1.95, up 7.44% from the prior year.
- Interest Coverage Ratio rose to 15.16 in Q2 2026, from 18.22 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 223.19 in Q4 2023 to a low of 50.65 in Q4 2022.
- A 5-year average of 5.29 and a median of 1.5 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 540.68% — and 2025, when it slumped 4005.45%.
- Tracing BCYC's Interest Coverage Ratio over 5 years: stood at 50.65 in 2022, then soared by 540.68% to 223.19 in 2023, then sank by 78.84% to 47.22 in 2024, then slumped by 113.95% to 6.59 in 2025, then plunged by 130.14% to 15.16 in 2026.
- The last three Interest Coverage Ratio figures came in at 15.16 (Q2 2026), 18.22 (Q1 2026), and 6.59 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -15.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.16 |
| Mar 31, 2026 | -18.22 |
| Dec 31, 2025 | -4.25 |
| Sep 30, 2025 | -21.30 |
| Jun 30, 2025 | -32.61 |
| Mar 31, 2025 | -21.15 |
| Dec 31, 2024 | -55.37 |
| Sep 30, 2024 | -1.47 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | 33.01 |
| Sep 30, 2023 | -1.71 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -1.20 |
| Dec 31, 2022 | 20.14 |
| Sep 30, 2022 | -0.68 |
| Jun 30, 2022 | -1.47 |
| Mar 31, 2022 | -33.48 |
| Dec 31, 2021 | -51.35 |
| Sep 30, 2021 | -0.11 |